Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Br J Clin Pharmacol. 2013 Aug;76(2):233-47. doi: 10.1111/bcp.12164.
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre-clinical development; buoyed by the recent licence approval of the anti-CTLA-4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.
癌症必须逃避或抑制免疫系统才能发展。更好地了解控制肿瘤检测和有效激活免疫系统（所谓的免疫调节检查点）的分子调控为癌症免疫治疗提供了新的靶点。针对这些靶点的治疗性单克隆抗体目前正在进行临床评估，更多的则处于临床前开发阶段；最近 CTLA-4 抗体伊匹单抗(ipilumumab)被批准用于黑色素瘤，这一进展令人鼓舞。本文将综述正在研究的各种抗体和靶分子的现状。
